Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 15/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25358167 | 1.00 | AKT1 (0.40) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL30494860 | 1.00 | AKT1 (0.40) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL30784462 | 0.88 | SOS1 (0.42) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL30495297 | 0.86 | AKT1 (0.52) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL25360674 | 0.86 | AKT1 (0.52) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL30783976 | 0.86 | AKT1 (0.52) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL25360677 | 0.86 | AKT1 (0.52) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL26041490 | 0.86 | AKT1 (0.42) | AKT1AKT2AKT3PTPN11PIK3CA | |
| SCHEMBL25360117 | 0.85 | AKT1 (0.41) | AKT1AKT2AKT3PTPN11 | |
| SCHEMBL25360112 | 0.85 | AKT1 (0.41) | AKT1AKT2AKT3PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |